昂利康(002940.SZ):創新藥注射用ALK-N001臨牀試驗申請獲得受理
格隆匯2月18日丨昂利康(002940.SZ)公佈,近日,浙江昂利康製藥股份有限公司收到國家藥品監督管理局簽發的注射用 ALK-N0011境內生產藥品註冊臨牀試驗《受理通知書》。
臨牀前研究結果顯示,注射用 ALK-N001 在多種不同腫瘤模型中對腫瘤有明顯的抑制作用,且具有良好的安全性,是一款極具創新性與開發潛力的小分子偶聯抗腫瘤藥物,有望爲晚期實體瘤患者提供新的治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.